Return to search results       New search       Contact for this trial
Study of regorafenib after sorafenib in patients with hepatocellular carcinoma
Trial ID: 15982
This clinical study evaluates the efficacy and safety of regorafenib in patients with advanced liver cancer who have progressed on sorafenib treatment.
Approximately 560 patients who meet the entry criteria will be randomly assigned in a 2:1 ratio to regorafenib or placebo (1/3 chance to receive placebo).
Primary endpoint of the study is overall survival.
Official Title: A randomized, double blind, placebo controlled, multicenter phase III study of regorafenib in patients with hepatocellular carcinoma (HCC) after sorafenib (RESORCE)
Product: Stivarga (Regorafenib, BAY73-4506)
Indication/Disease: Carcinoma, Hepatocellular
Trial Status: Active, not recruiting
Trial Start Date: 2013-05-14
Trial End Date: 2018-02-28 (Anticipated)
Trial Phase: Phase 3
Trial Design:
Trial Type: Interventional
Intervention: Drug
Trial Purpose: Treatment
Trial Endpoint: Safety/Efficacy
Allocation: Randomized
Blinding: Double Blind
Assignment: Parallel Assignment
Trial Arms: 2
Participants: 573
Primary Outcome:
  • Overall survival
    Timeframe: Approximately 33 months.
Secondary Outcome:
  • Disease control
    Timeframe: Approximately 33 months.
  • Objective tumor response
    Timeframe: Approximately 33 months.
  • Progression free survival (PFS)
    Timeframe: Approximately 33 months.
  • Time to progression
    Timeframe: Approximately 33 months.
Eligibility Criteria:
Minimum Age: 18 Years
Maximum Age: N/A
Gender: Both
Healthy Volunteers: No

Inclusion Criteria:
  • Histological or cytological confirmation of HCC (hepatocellular carcinoma) or non-invasive diagnosis of HCC as per American Association for the Study of Liver Diseases criteria in patients with a confirmed diagnosis of cirrhosis
  • Barcelona Clinic Liver Cancer stage Category B or C that cannot benefit from treatments of established efficacy with higher priority such as resection, local ablation, chemoembolization or systemic sorafenib.
  • Failure to prior treatment with sorafenib (defined as documented radiological progression according to the radiology charter). Randomization needs to be performed within 10 weeks after the last treatment with sorafenib.
  • Tolerability of prior treatment with sorafenib defined as not less than 20 days at a minimum daily dose of 400 mg QD within the last 28 days prior to withdrawal.
  • Liver function status Child-Pugh Class A. Child Pugh status should be calculated based on clinical findings and laboratory results during the screening period.
Local or loco-regional therapy of intrahepatic tumor lesions (e.g. surgery, radiation therapy, hepatic arterial embolization, chemoembolization, radiofrequency ablation, percutaneous ethanol injection, or cryoablation) must have been completed >/=4 weeks before first dose of study medication. Note: patients who received sole intrahepatic intraarterial chemotherapy, without lipiodol or embolizing agents are not eligible.
  • Eastern Cooperative Oncology Group Performance Status of 0 or 1.
  • Adequate bone marrow, liver and renal function as assessed by the following laboratory tests conducted within 7 days before randomization.
  • Glomerular filtration rate >/= 30 ml/min/1.73 m2 according to the Modification of diet in renal disease study equation.
  • At least one uni-dimensional measurable lesion by computed tomography (CT) scan or magnetic resonance imaging (MRI) according to RECIST (RECIST version 1.1), and modified RECIST for HCC. Tumor lesions situated in a previously irradiated area, or in an area subjected to other loco-regional therapy, may be considered measurable if there has been demonstrated progression in the lesion.
  • Life expectancy of at least 3 months.
  • Women of childbearing potential and men must agree to use adequate contraception .
Exclusion Criteria :
  • Sorafenib treatment within 2 weeks of randomization.
  • Prior systemic treatment for HCC, except sorafenib.
  • Permanent discontinuation of prior sorafenib therapy due to sorafenib related toxicity.
  • Known history or symptomatic metastatic brain or meningeal tumors (head CT or MRI at screening to confirm the absence of central nervous system [CNS] disease if patient has symptoms suggestive or consistent with CNS disease).
  • Uncontrolled hypertension (systolic blood pressure [BP] > 150 mmHg or diastolic pressure > 90 mmHg despite optimal medical management).
  • Uncontrolled ascites (defined as not easily controlled with diuretic or paracentesis treatment).
  • Ongoing infection > Grade 2 according to NCI-CTCAE (National Cancer Institute - Common Terminology Criteria for Adverse Events) v. 4.0. Hepatitis B is allowed if no active replication is present. Hepatitis C is allowed if no antiviral treatment is required.
  • Clinically significant bleeding NCI-CTCAE version 4.0 Grade 3 or higher within 30 days before randomization.
  • Arterial or venous thrombotic or embolic events such as cerebrovascular accident (including transient ischemic attacks), deep vein thrombosis or pulmonary embolism within 6 months before the start of study medication.
  • Patients unable to swallow oral medications.
  • Interstitial lung disease with ongoing signs and symptoms at the time of screening.
Additional Information: Regorafenib BAY73-4506
Sponsor: Bayer
AustraliaActive, not recruiting
AustriaActive, not recruiting
Czech RepublicActive, not recruiting
ChinaActive, not recruiting
RussiaActive, not recruiting
HungaryActive, not recruiting
JapanActive, not recruiting
SwitzerlandActive, not recruiting
United KingdomActive, not recruiting
Korea, Republic OfActive, not recruiting
BrazilActive, not recruiting
TaiwanActive, not recruiting
ItalyActive, not recruiting
SpainActive, not recruiting
FranceActive, not recruiting
United StatesActive, not recruiting
GermanyActive, not recruiting
Relevant Links: Click here and search results for studies related to Bayer products.Click here and search for drug information provided by the FDA.Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.
This information is provided by Bayer under Bayer's disclaimer for publication of clinical trial information.